NexImmune is a publicly traded, clinical stage biotechnology company developing unique approaches to T cell immunotherapies based on its propriety Artificial Immune Modulation (AIM™) technology.  NexImmune has a differentiated platform and pipeline of product candidates in pre-clinical and phase 1/2 stages with lead programs focused on the treatment of relapsed acute myeloid leukemia (AML) after allogenic stem cell transplantation and multiple myeloma refractory to >3 prior lines of therapy. The AIM technology enables NexImmune to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response. By mimicking natural T cell biology, NexImmune’s T cell product candidates are designed to combine the attributes of cellular precision, potency, and persistence with reduced potential for undesired toxicities.  For the last decade, the AIM platform has evolved into a stable platform for various therapy targets providing an opportunity to make a massive impact due to its adaptability and flexibility in oncology, autoimmune disorders, infectious disease, and beyond. 

Irving Investors

ArrowMark Partners

Piedmont Capital Partners

Barer & Son Capital

Amgen Ventures

Pfizer Venture Investments

New Enterprise Associates

NexImmune, Inc.

NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a candidate targeted against HPV-associated malignancies, which is in preclinical stage. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Nov 4, 2024 10:53 AM	042f5355
crunchbase profile	general
li profile	general	Feb 2, 2024 9:28 PM	bac4e46d
translate crunchbase fundingrounds	general
peers	general	Feb 2, 2024 9:28 PM	58c12f79
news basic	general
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:NEXIMMUNE

NexImmune

Last Close

0.22

21/11 20:00

Market Cap

3.17M

Beta: -

Volume Today

60

Avg: -